Posted by Michael Wonder on 21 Apr 2019
NICE publishes final recommendation for Almirall's Ilumetri (tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis
17 April 2019 - Tildrakizumab was approved by the European Commission in September 2018, is already available in Germany and is due to be marketed in all EU Member states.
Almirall announced today that the NICE has published its final guidance approving Ilumetri (tildrakizumab), a humanised, high-affinity IL-23p19 monoclonal antibody, for treating adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Following a single health technology assessment submission to NICE in August 2018 and the subsequent questions for clarification and appraisal committee meetings, NICE completed their assessment of tildrakizumab and has recommended tildrakizumab as a cost effective treatment option for the NHS for the patients specified in the Final Appraisal Determination.
